Limits...
Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.

Brenner B, Siris N, Rakowsky E, Fenig E, Sulkes A, Lurie H - Br. J. Cancer (2002)

Bottom Line: At a median follow-up of 57 months, the 5-year overall survival for the entire group and the disease-free survival for the 94 operated patients were 65% and 53%, respectively.Univariate analysis identified 10 prognostic factors of overall and disease-free survival, of which four retained significance on multivariate analysis: inflammatory breast cancer (P=0.0000, P=0.0004, respectively), baseline tumour markers (P=0.003 for both), post-chemotherapy number of involved nodes (P=0.003; P=0.017) and extracapsular spread (P=0.052; P=0.014).In conclusion, besides inflammatory features, baseline tumour markers and post-chemotherapy nodal status are strong predictors of outcome in locally advanced breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel. brennerb@bezeqint.net

Show MeSH

Related in: MedlinePlus

Disease-free survival (A) and overall survival (B) by presence of inflammatory breast cancer (IBC).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376279&req=5

fig1: Disease-free survival (A) and overall survival (B) by presence of inflammatory breast cancer (IBC).

Mentions: The univariate analysis of the pretreatment clinical prognostic factors is shown in Table 2Table 2Survival by pretreatment characteristics: Univariate analysis. Four factors were found to significantly correlate with poorer outcome (OS and DFS): clinical tumour size larger than 5 cm, inflammatory features, high grade, and elevated levels of baseline markers. Inflammatory carcinoma had the strongest impact, decreasing the estimated 5-year OS from 79 to 27% (Figure 1Figure 1


Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.

Brenner B, Siris N, Rakowsky E, Fenig E, Sulkes A, Lurie H - Br. J. Cancer (2002)

Disease-free survival (A) and overall survival (B) by presence of inflammatory breast cancer (IBC).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376279&req=5

fig1: Disease-free survival (A) and overall survival (B) by presence of inflammatory breast cancer (IBC).
Mentions: The univariate analysis of the pretreatment clinical prognostic factors is shown in Table 2Table 2Survival by pretreatment characteristics: Univariate analysis. Four factors were found to significantly correlate with poorer outcome (OS and DFS): clinical tumour size larger than 5 cm, inflammatory features, high grade, and elevated levels of baseline markers. Inflammatory carcinoma had the strongest impact, decreasing the estimated 5-year OS from 79 to 27% (Figure 1Figure 1

Bottom Line: At a median follow-up of 57 months, the 5-year overall survival for the entire group and the disease-free survival for the 94 operated patients were 65% and 53%, respectively.Univariate analysis identified 10 prognostic factors of overall and disease-free survival, of which four retained significance on multivariate analysis: inflammatory breast cancer (P=0.0000, P=0.0004, respectively), baseline tumour markers (P=0.003 for both), post-chemotherapy number of involved nodes (P=0.003; P=0.017) and extracapsular spread (P=0.052; P=0.014).In conclusion, besides inflammatory features, baseline tumour markers and post-chemotherapy nodal status are strong predictors of outcome in locally advanced breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel. brennerb@bezeqint.net

Show MeSH
Related in: MedlinePlus